8-K current report · filed Aug 10, 2026

ACCENDRA HEALTH INC/VA/ (ACH) 8-K Current Report: August 10, 2026

Item 2.02Item EX-99.1Item EX-99.2Item 7.01ACH overview

Short answer

ACCENDRA HEALTH INC/VA/ (ACH) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Q2 and six-month financial results through June 30, 2026 announced on August 10, 2026.

ACCENDRA HEALTH INC/VA/ 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 and six-month financial results through June 30, 2026 announced on August 10, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, cash flow and updated outlook details

Item 7.01 · Regulation FD Disclosure

  • Earnings presentation posted August 10, 2026, providing investors supplemental fiscal 2026 performance information
  • Exhibit 99.2 contains the substantive financial and operating disclosures associated with the presentation

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $613.2M, down from $681.9M; adjusted EBITDA $60.1M versus $96.6M
  • Q2 adjusted loss $14.3M, or $0.19 per share, versus adjusted income $20.5M previously
  • Debt reduced $385M to $1.718B, but cash fell to $7.7M and net debt remained $1.710B
  • 2026 guidance: revenue $2.45B-$2.55B, adjusted EBITDA $300M-$320M, free cash flow breakeven to slightly positive
  • CEO Edward Pesicka intends to retire and leave the board by year-end 2026, creating leadership-transition risk

Item EX-99.2 · Exhibit EX-99.2

  • Q2 2026 continuing-operations loss $89M, adjusted EBITDA $60M, free cash flow negative $25M
  • Six-month adjusted EBITDA $118M versus $193M, free cash flow negative $27M versus positive $51M
  • Funded debt reduced to $1.753B from $2.123B, while weighted average debt life extended to approximately 5.5 years from 2.7 years
  • 2026 outlook: revenue $2.45B-$2.55B, adjusted EBITDA $300M-$320M, interest expense $142M-$146M
  • Full-year free cash flow outlook breakeven to slightly positive, with cash interest expense expected at $158M-$162M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ACCENDRA HEALTH INC/VA/ 8-K filings

Get the next ACH 8-K as it lands

Follow ACH for push alerts, or ask the research agent what this filing means.